 - Enrollment and dosing complete in Phase 1a clinical trial of PT101 ; top-line results expected early 2021 - PT627 s ystemic PD-1 agonist development candidate nominated; IND-enabling studies expected to initiate 4Q 2020 - Presented preclinical data at FOC I S 2020 highlighting potential of TALON platform in autoimmune disease 